1
Clinical Trials associated with Human Hepatitis B Immunoglubolin (Weiguang Biological)静注乙型肝炎人免疫球蛋白(pH4)联合拉米夫定预防肝移植术后乙肝复发的多中心、单臂临床研究
[Translation] A multicenter, single-arm clinical study of intravenous hepatitis B human immunoglobulin (pH4) combined with lamivudine to prevent hepatitis B recurrence after liver transplantation
评价深圳市卫武光明生物制品有限公司生产的静注乙型肝炎人免疫球蛋白(pH4)联合拉米夫定预防乙肝相关性肝病肝移植术后乙肝复发的临床有效性和安全性
[Translation] To evaluate the clinical efficacy and safety of intravenous hepatitis B human immunoglobulin (pH4) produced by Shenzhen Weiwu Guangming Biological Products Co., Ltd. combined with lamivudine in preventing hepatitis B recurrence after liver transplantation for hepatitis B-related liver disease
Start Date- |
Sponsor / Collaborator- |
100 Clinical Results associated with Human Hepatitis B Immunoglubolin (Weiguang Biological)
100 Translational Medicine associated with Human Hepatitis B Immunoglubolin (Weiguang Biological)
100 Patents (Medical) associated with Human Hepatitis B Immunoglubolin (Weiguang Biological)
100 Deals associated with Human Hepatitis B Immunoglubolin (Weiguang Biological)